About HalioDx
HalioDx is a company based in Marseille (France) founded in 2015 was acquired by Veracyte in June 2021. HalioDx has raised $31.31 million across 4 funding rounds from investors including Xiaomi, Amundi and Veracyte. HalioDx operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Marseille, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of HalioDx
Unlock access to complete
Unlock access to complete
Funding Insights of HalioDx
HalioDx has successfully raised a total of $31.31M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HalioDx
HalioDx has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Xiaomi, Amundi and Veracyte.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to French companies by the firm.
|
Locked | Locked | Locked | |
|
Equity investments are provided by SOFIPACA for regional business growth.
|
Locked | Locked | Locked | |
|
Growth-stage life sciences and tech companies in Europe are funded.
|
Locked | Locked | Locked |
Investor details for HalioDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HalioDx
Investment portfolio details for HalioDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HalioDx
Detailed financials for HalioDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Haliodx Comparisons
Peer comparison for HalioDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HalioDx
HalioDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
Detailed competitors of HalioDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Haliodx
Complete news archive for HalioDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HalioDx
HalioDx was founded in 2015.
HalioDx is headquartered in Marseille, France. It is registered at Marseille, Provence-alpes-cote D'azur, France.
HalioDx is a funded company, having raised a total of $31.31M across 4 funding rounds to date.
HalioDx was founded in 2015 in Marseille, France, within the oncology diagnostics sector. Products focused on colon cancer are developed, including assays that assess disease severity, predict treatment responses, and classify tumors molecularly. A range of immunologic scoring tests is offered, such as Immunoscore for colon cancer and non-small cell lung cancer, supporting clinical evaluations in the field.
HalioDx's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
HalioDx has 11 investors. Key investors include Xiaomi, Amundi, Veracyte, European Union, and Quest for Growth.